Frequent mutation of p16 in squamous cell carcinoma of the head and neck

Laryngoscope

Volumn 108, Issue 6, 1998, Pages 923-928

  Lang, Jas C ^a   Tobin, Evan J ^a   Knobloch, Tom J ^a   Schuller, David E ^a   Bartynski, Kevin J ^a   Mountain, Rodney E ^a   Nicholson, Roy ^a   DeYoung, Barry R ^a   Weghorst, Christopher M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Head and neck cancer; P16; RB; RT PCR; Tumor suppressor

Indexed keywords

PROTEIN P16;

ARTICLE; CONTROLLED STUDY; GENE ISOLATION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, P16; HEAD AND NECK NEOPLASMS; HUMANS; POINT MUTATION; RETINOBLASTOMA;

EID: 0031863635     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199806000-00024     Document Type: Article

References (23)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1993. Cancer J Clin 1993;43:7-26.
2. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989;4:1463-8.
3. Lucas JM, Bryans M, Lo K, Wilkie NM, Freshney M, Thornton D, Lang JC. The FGF-4 promoter is required for transformation and is active in both embryonal and somatic cells. Oncol Res 1994;6:139-49.
4. Field JK. Spandidos DA, Donckerwolcke RA. Overexpression of p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 1992;339:502-3.
5. Yoo GH, Xu JJ, Brennan JA, et al. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 1994;54:4603-6.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
8. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 1994;54:5816-20.
9. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL. Cancer-associated mis-sense and deletion mutations impair p16Ink4 CDK inhibitory activity. Int J Cancer 1996;66: 249-54.
10. Enders GH, Koh J, Missero C, Rustgi AK, Harlow E. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 1996;12:1239-45
11. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
12. Mori T, Kiura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-7.
13. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
14. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. Involvement of CDKN2 (p16Ink4A/MTS1) and p15Ink4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995;55: 1436-40.
15. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ. Reciprocal Rb inactivation and p16Ink4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9.
16. Zhang S-Y, Klein-Szanto A, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994;54:5050-3.
17. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
18. Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogens 1997;14:811-8.
19. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995;85: 2685-90.
20. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995;55: 2713-8.
21. Gramza AW, Lucas JM, Mountain RE, Schuller DE, Lang JC. Efficient method for preparing normal and tumor tissue for RNA extraction. BioTechniques 1995;18:228-9.
22. Okamoto A, Demetrick DJ, Spillare EA, et al. p16INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59:49-57.
23. Merlo A, Herman JG, Mao L, et al. 5′ CgG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995;1:686-92.